Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

Table 6

Overall response for Trastuzumab, Lapatinib, Erlotinib, and Gefitinib combination therapies with chemotherapeutic agents [34, 40–43].

Study	No. of patients	Chemotherapy	Dose	OR (%)
Trastuzumab
Slamon et al. [34]	143	Doxorubicin	Trastuzumab (4 mg/kg initial dose, 2 mg/kg weekly)	56
			Doxorubicin (60 mg/m^2)
	92	Paclitaxel	Trastuzumab (4 mg/kg initial dose, 2 mg/kg weekly)	41
			Paclitaxel (175 mg/m^2)
Marty et al. [43]	186	Docetaxel	Trastuzumab (4 mg/kg initial dose, 2 mg/kg weekly)	34
			Docetaxel (100 mg/m^2 triweekly)
Lapatinib
Geyer et al. [40]	163	Capecitabine	Lapatinib (1250 mg/day)	22*
			Capecitabine (2000 mg/m^2)
Erlotinib
Twelves et al. [41]	24	Capecitabine, docetaxel	Erlotinib (100 mg/day)	68
			Capecitabine (825 mg/m^2)
			Docetaxel (75 mg/m^2)
Gefitinib
Ciardiello et al. [42]	41	Docetaxel	Geftinib (250 mg/day)	54
			Docetaxel (75 mg/m^2 or 100 mg/m^2)

OR: Overall response rate.
*Study was performed in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy.